Evaluation of UHRF1 and P16INK4A expression levels in newly diagnosed AML patients. Biomedical Research and Therapy, [S. l.], v. 5, n. 9, p. 2658–2663, 2018. DOI: 10.15419/bmrat.v5i9.475. Disponível em: https://preservation.bmrat.org/index.php/BMRAT/article/view/475.. Acesso em: 14 nov. 2024.